72. Pituitary ADH secretion disorder Clinical trials / Disease details

Clinical trials : 40 / Drugs : 28 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 9

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03202667 (ClinicalTrials.gov)	December 15, 2017	27/6/2017	Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study	Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study	SIAD - Syndrome of Inappropriate Antidiuresis;Hyponatremia	Drug: Empagliflozin 25mg;Drug: Placebo	University Hospital, Basel, Switzerland	NULL	Completed	18 Years	N/A	All	17	Phase 2/Phase 3	Switzerland
2	NCT02729766 (ClinicalTrials.gov)	March 2016	24/3/2016	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study	Inappropriate ADH Syndrome	Other: Induced hypotonic hyponatremia - SIAD model;Drug: Empagliflozin 25mg Tbl;Drug: Placebo P-Tablet	University Hospital, Basel, Switzerland	NULL	Completed	18 Years	65 Years	Both	15	Phase 2/Phase 3	Switzerland